Table IV.
Relative Potencies of Topical Corticosteroids*
| Class | Drug | Dosage Form(s) | Strength (%) |
|---|---|---|---|
| I. Very High Potency | Augmented betamethasone dipropionate | Ointment | 0.05 |
| Clobetasol propionate | Cream, foam, ointment | 0.05 | |
| Diflorasone diacetate | Ointment | 0.05 | |
| Halobetasol propionate | Cream, ointment | 0.05 | |
| II. High Potency | Amcinonide | Cream, lotion, ointment | 0.1 |
| Augmented betamethasone dipropionate | Cream | 0.05 | |
| Betamethasone dipropionate | Cream, foam, ointment, solution | 0.05 | |
| Desoximetasone | Cream, ointment | 0.25 | |
| Desoximetasone | Gel | 0.05 | |
| Diflorasone diacetate | Cream | 0.05 | |
| Fluocinonide | Cream, gel, ointment, solution | 0.05 | |
| Halcinonide | Cream, ointment | 0.1 | |
| Mometasone furoate | Ointment | 0.1 | |
| Triamcinolone acetonide | Cream, ointment | 0.5 | |
| III-IV. Medium Potency | Betamethasone valerate | Cream, foam, lotion, ointment | 0.1 |
| Clocortolone pivalate | Cream | 0.1 | |
| Desoximetasone | Cream | 0.05 | |
| Fluocinolone acetonide | Cream, ointment | 0.025 | |
| Flurandrenolide | Cream, ointment | 0.05 | |
| Fluticasone propionate | Cream | 0.05 | |
| Fluticasone propionate | Ointment | 0.005 | |
| Mometasone furoate | Cream | 0.1 | |
| Triamcinolone acetonide | Cream, ointment | 0.1 | |
| V. Lower-Medium Potency | Hydrocortisone butyrate | Cream, ointment, solution | 0.1 |
| Hydrocortisone probutate | Cream | 0.1 | |
| Hydrocortisone valerate | Cream, ointment | 0.2 | |
| Prednicarbate | Cream | 0.1 | |
| VI. Low Potency | Alclometasone dipropionate | Cream, ointment | 0.05 |
| Desonide | Cream, gel, foam, ointment | 0.05 | |
| Fluocinolone acetonide | Cream, solution | 0.01 | |
| VII. Lowest Potency | Dexamethasone | Cream | 0.1 |
| Hydrocortisone | Cream, lotion, ointment, solution | 0.25, 0.5, 1 | |
| Hydrocortisone acetate | Cream, ointment | 0.5–1 | |
Reprinted with permission from Paller AS, Mancini AJ. Eczematous eruptions in childhood. In: Paller AS, Mancini AJ. Hurwitz Clinical Pediatric Dermatology. St. Louis, MO: Elsevier Inc; 2011 chapter 3, p.49.
Includes representative examples and not all available agent